Evidence supporting the use of: Polyunsaturated fatty acid
For the health condition: Blood Clots (prevention of)

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Polyunsaturated fatty acids (PUFAs), particularly the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been studied for their role in the prevention of blood clots (thrombosis). Scientific evidence suggests that omega-3 PUFAs exert antithrombotic effects through multiple mechanisms, including the reduction of platelet aggregation, lowering of plasma triglyceride levels, and modulation of endothelial function. Several randomized controlled trials and meta-analyses have demonstrated that omega-3 supplementation can reduce platelet activity and may modestly reduce the risk of cardiovascular events related to thrombosis, though results are sometimes inconsistent.

The American Heart Association recognizes the potential benefits of omega-3 fatty acids for cardiovascular health, including their antithrombotic properties, and recommends their consumption in certain patient populations. However, the magnitude of the effect on primary prevention of blood clots in the general population remains moderate, and not all studies have shown a significant reduction in thrombotic events. Some large-scale trials have shown only modest or no effect on clinical endpoints such as stroke or myocardial infarction. Overall, while there is scientific rationale and moderate-quality evidence supporting the use of polyunsaturated fatty acids, especially omega-3s, for blood clot prevention, the strength of evidence is not absolute.

More about Polyunsaturated fatty acid
More about Blood Clots (prevention of)

Products containing Polyunsaturated fatty acid

We currently have no products on Vitabase that contain this ingredient.